This review focuses on two main areas: the combined and repurposed use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) and immune checkpoint inhibitors (ICIs) in ovarian cancer, as well as the potential of nanomedicine as a novel approach to drug delivery. This evidence concerns the gene PARP1 and ovarian carcinoma.